Literature DB >> 9714126

Antibody titers against oxidized LDL are not elevated in patients with familial hypercholesterolemia.

J Hulthe1, J Wikstrand, A Lidell, I Wendelhag, G K Hansson, O Wiklund.   

Abstract

Antibodies against oxidized low density lipoproteins (Ox-LDLs) have been proposed to be independent predictors of atherosclerosis development. The main aims of the current study were to (1) compare antibody titers to Ox-LDL in patients with heterozygous familial hypercholesterolemia (n=51) with those in matched controls (n=45) and (2) analyze whether the antibody titers were related to the extent of atherosclerosis, as assessed cross-sectionally and prospectively by ultrasonography in the 2 study groups. Antibody titers were determined with a solid-phase ELISA, and plates were coated with the antigens Ox-LDL or malondialdehyde-treated LDL (MDA-LDL) as well as with the postcoat only (5% dry milk powder). Antibody titers were expressed as absorbance [(value in patient serum minus that in postcoat) divided by (Internal Standard Serum minus postcoat)]. There were no significant differences in antibody titers against Ox-LDL or MDA-LDL between the group of patients with familial hypercholesterolemia and the controls. In cross-sectional comparisons, no significant associations were observed between the intima-media thickness of the carotid or femoral arteries and antibody titers against Ox-LDL or between plaque occurrence and these titers. Patients with a history of myocardial infarction had significantly lower IgM titers against Ox-LDL compared with patients without a history of myocardial infarction and with controls. In conclusion, mean values for antibody titers against Ox-LDL were not increased in the patient group compared with a healthy control group, and no positive, significant relationship was observed between antibody titers and the extent of atherosclerosis, as measured by ultrasound, in the carotid or femoral arteries. Taken together, these findings indicate that the relationship between the autoimmune response to Ox-LDL and the extent of atherosclerosis is more complex than previously anticipated.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9714126     DOI: 10.1161/01.atv.18.8.1203

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  7 in total

Review 1.  Lipoprotein autoantibodies: measurement and significance.

Authors:  Gabriel Virella; Maria F Lopes-Virella
Journal:  Clin Diagn Lab Immunol       Date:  2003-07

2.  The autoantibody repertoire against copper- or macrophage-modified LDL differs in normolipidemics and hypercholesterolemic patients.

Authors:  Eva C Fernvik; Daniel F J Ketelhuth; Momtchilo Russo; Magnus Gidlund
Journal:  J Clin Immunol       Date:  2004-03       Impact factor: 8.317

Review 3.  The immune system in atherosclerosis.

Authors:  Göran K Hansson; Andreas Hermansson
Journal:  Nat Immunol       Date:  2011-03       Impact factor: 25.606

4.  Endothelial vasodilatory function is predicted by circulating apolipoprotein B and HDL in healthy humans.

Authors:  Peter Steer; Johannes Hulthe; Jonas Miligård; Dennis M Sarabi; Samar Basu; Bengt Vessby; Lars Lind
Journal:  Lipids       Date:  2002-12       Impact factor: 1.880

Review 5.  Clinical significance of the humoral immune response to modified LDL.

Authors:  Maria F Lopes-Virella; Gabriel Virella
Journal:  Clin Immunol       Date:  2009-05-08       Impact factor: 3.969

6.  Antioxidized LDL antibodies are associated with different metabolic pathways in patients with atherosclerotic plaque and type 2 diabetes.

Authors:  M Rosa Bernal-Lopez; Lourdes Garrido-Sanchez; Victor Gomez-Carrillo; Jose Luis Gallego-Perales; Vicenta Llorente-Cortes; Fernando Calleja; Ricardo Gomez-Huelgas; Lina Badimon; Francisco J Tinahones
Journal:  Diabetes Care       Date:  2012-11-27       Impact factor: 19.112

7.  Immune response to lipoproteins in atherosclerosis.

Authors:  Sonia Samson; Lakshmi Mundkur; Vijay V Kakkar
Journal:  Cholesterol       Date:  2012-08-23
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.